Molecular basis for the mechanism of action of an anti‐TACE antibody
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Inhibitors of tumor necrosis factor-α converting enzyme (TACE) have potential as therapeutics for various diseases. Many small molecule inhibitors, however, exhibit poor specificity profiles because they target the highly conserved catalytic cleft of TACE. We report for the first time the molecular interaction of a highly specific anti-TACE antagonistic antibody (MEDI3622). We characterized the binding of MEDI3622 using mutagenesis, as well as structural modeling and docking approaches. We show that MEDI3622 recognizes a unique surface loop of sIVa-sIVb β-hairpin on TACE M-domain, but does not interact with the conserved catalytic cleft or its nearby regions. The exquisite specificity of MEDI3622 is mediated by this distinct structural feature on the TACE M-domain. These findings may aid the design of antibody therapies against TACE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Determination of the epitope of MEDI3622 at a molecular level. (A) Amino acid alignment of the M-domains of human TACE and ADAM10. Their identical and similar amino acids are shown as green and blue, respectively. Secondary structural elements are shown according to the crystal structure of TACE M-domain,8 with arrows for β-strands, solid boxes for helices and lines for loops. Segments denoted as A-J with dotted lines were swapped between TACE and ADAM10 to construct chimeric variants. (B) Binding characterization of MEDI3622 to TACE/ADAM10 chimeric variants using SPR. Binding was calculated as % binding compared to wild-type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Replacing the segment E with the ADAM10 residues abolished the binding of MEDI3622 (LoF_E), while grafting it to ADAM10 led to the recognition of MEDI3622 (GoF_E). Results represent the means of 3 independent experiments with error bars indicating standard deviations. (C) Determination of MEDI3622s binding to full-length TACE variants by FACS. Expression levels of TACE and its variants were monitored using anti-TACE polyclonal antibody. The y axis represents side scatter characteristics, and the x axis represents the mean fluorescence intensity. Mock control staining was used to set gates; numbers in gates reflect the percentage of positive cells. MEDI3622 did not recognize the full-length TACE chimeric variant encoding for the segment E of ADAM10.](https://figures.cochat.ai/paper-figures/55aa37e668664db3b1105fe3a5b13ae2/molecular-basis-for-the-mechanism-of-action-of-an-antitace-antibody-figure-2.jpg)

![Figure 4. Proposed binding mode of MEDI3622. (A) Three-dimensional model of MEDI3622 bound to TACE. The identified epitope of MEDI3622 (P366-N381) (cyan) adopts a β-hairpin loop conformation projecting from the central body of M-domain (magenta). TACE residues Y370 and Y379 (cyan) along with conserved histidines H405, H409, H415 (yellow) are shown in sticks. The Zn ion is shown as a green sphere. MEDI3622 (VH in orange, VL in beige) binds to TACE through interacting with the sIVa-sIVb β-hairpin loop, with the sIVa strand (Y369Y370S371) located in the center of the binding interface. (B) Binding of MEDI3622 to TACE alanine mutants. Two stretches of amino acids were mutated into alanines, including Y369Y370S371 (sIVa strand, the center of the binding interface) and N377I378Y379 (sIVb strand, peripheral to the binding interface). The alanine variants were expressed as soluble proteins and their binding profiles with MEDI3622 were characterized using SPR. Binding was calculated as % binding compared to wild type TACE after normalization of expression levels using the following formula: [(Response TACE variants MEDI3622/Response TACE wildtype MEDI3622)/(Response TACE variants polyAb/Response TACE wildtype polyAb)] *100. Binding of MEDI3622 to TACE was abolished when mutating residues Y369Y370S371 to alanines, while its binding was retained upon mutating residues N377I378Y379. Results represent the means of 3 independent experiments with error bars indicating standard deviations.](https://figures.cochat.ai/paper-figures/a0119317307c48229f20ba65627a0078/molecular-basis-for-the-mechanism-of-action-of-an-antitace-antibody-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MEDI3622 (anti‐TACE antibody) showed promising preclinical activity in human colorectal adenocarcinoma progression [148, 149].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Canonical structures for the hypervariable regions of immunoglobulins
Chothia, C., & Lesk, A. M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90412-8 · Cited by 1,406 · cited 1×
“CDRs are shown in bold and underlined according to Chothia definition.(29) (B) Modeled 3-dimensional structure of MEDI3622 variable domains, with VH in orange and VL in beige.”
BackgroundZDOCK: An initial‐stage protein‐docking algorithm
Chen, R., Li, L., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10389 · Cited by 1,393
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
Moss, M. L., Jin, S.-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W.-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., et al. (1997) · Nature · doi:10.1038/385733a0 · Cited by 1,378 · cited 1×
“It was initially identified as a convertase for tumor necrosis factor-a, a immunomodulatory and proinflammatory cytokine.(2,3) It has also been shown to catalyze the release of various epidermal growth factors (EGF),(4,5) including amphiregulin, heparin-binding EGF-like growth factor, epiregulin, and epigen, which are…”
BackgroundEDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161 · cited 1×
“TACE (tumor necrosis factor-a converting enzyme, also known as ADAM17) is a membrane-bound metalloprotease responsible for ectodomain shedding of pathologically significant substrates.(1) It was initially identified as a convertase for tumor necrosis factor-a, a immunomodulatory and proinflammatory cytokine.”
BackgroundDistinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
Sahin, U., Weskamp, G., Kelly, K., Zhou, H.-M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., & Blobel, C. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307137 · Cited by 979
Janes, P. W., Saha, N., Barton, W. A., Kolev, M. V., Wimmer-Kleikamp, S. H., Nievergall, E., Blobel, C. P., Himanen, J.-P., Lackmann, M., & Nikolov, D. B. (2005) · Cell · doi:10.1016/j.cell.2005.08.014 · Cited by 443
Sunnarborg, S. W., Hinkle, C. L., Stevenson, M., Russell, W. E., Raska, C. S., Peschon, J. J., Castner, B. J., Gerhart, M. J., Paxton, R. J., Black, R. A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112050200 · Cited by 413
Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme
Maskos, K., Fernandez-Catalan, C., Huber, R., Bourenkov, G. P., Bartunik, H., Ellestad, G. A., Reddy, P., Wolfson, M. F., Rauch, C. T., Castner, B. J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3408 · Cited by 387 · cited 3×
“These inhibitors interact with the conserved catalytic cleft located on the surface of the ellipsoid-shaped M domain.(7,8,17,18) The catalytic cleft contains a catalytic zinc (Zn) ion at its center, coordinated by 4 highly conserved residues (H(405), E(406), H(409), H(415)) typical of a Zn-binding motif (HEXXHXXGXXHD…”
BackgroundRDOCK: Refinement of rigid‐body protein docking predictions
Li, L., Chen, R., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10460 · Cited by 330
Martin, A. C. R., & Thornton, J. M. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0617 · Cited by 246
Althoff, K., Reddy, P., Voltz, N., Rose‐John, S., & Müllberg, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01278.x · Cited by 162
Hinkle, C. L., Sunnarborg, S. W., Loiselle, D., Parker, C. E., Stevenson, M., Russell, W. E., & Lee, D. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312141200 · Cited by 153
Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5
Mosyak, L., Georgiadis, K. E., Shane, T., Svenson, K., Hebert, T., McDonagh, T., Mackie, S. A., Olland, S., Lin, L., Zhong, X., et al. (2008) · Protein Science · doi:10.1110/ps.073287008 · Cited by 149
Current perspective of TACE inhibitors: A review
DasGupta, S., Murumkar, P. R., Giridhar, R., & Yadav, M. R. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.11.067 · Cited by 127 · cited 3×
“These inhibitors interact with the conserved catalytic cleft located on the surface of the ellipsoid-shaped M domain.(7,8,17,18) The catalytic cleft contains a catalytic zinc (Zn) ion at its center, coordinated by 4 highly conserved residues (H(405), E(406), H(409), H(415)) typical of a Zn-binding motif (HEXXHXXGXXHD…”
BackgroundCross-domain inhibition of TACE ectodomain
Tape, C. J., Willems, S. H., Dombernowsky, S. L., Stanley, P. L., Fogarasi, M., Ouwehand, W., McCafferty, J., & Murphy, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017067108 · Cited by 117 · cited 2×
“The binding mode of MEDI3622 also differs from previously reported anti-TACE inhibitory mAbs, D1(A12) and A9.”
MethodWisniewska, M., Goettig, P., Maskos, K., Belouski, E., Winters, D., Hecht, R. I., Black, R. A., & Bode, W. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.088 · Cited by 112 · cited 2×
“These inhibitors interact with the conserved catalytic cleft located on the surface of the ellipsoid-shaped M domain.(7,8,17,18) The catalytic cleft contains a catalytic zinc (Zn) ion at its center, coordinated by 4 highly conserved residues (H(405), E(406), H(409), H(415)) typical of a Zn-binding motif (HEXXHXXGXXHD…”
BackgroundGerhardt, S., Hassall, G., Hawtin, P., McCall, E. J., Flavell, L., Minshull, C. A., Hargreaves, D., Ting, A. K. T., Pauptit, R. A., Parker, A. E., et al. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.07.047 · Cited by 106
High Resolution Crystal Structure of the Catalytic Domain of ADAMTS-5 (Aggrecanase-2)
Shieh, H., Mathis, K. J., Williams, J. M., Hills, R. L., Wiese, J. F., Benson, T. E., Kiefer, J. R., Marino, M. H., Carroll, J. N., Leone, J. W., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705879200 · Cited by 81
Liu, H., Shim, A. H. R., & He, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014258 · Cited by 68 · cited 1×
“The M-domain is shown in magenta for TACE (PDB 3E8R),(16) blue for ADAMTS-5 (PDB 3LJT),(30) cyan for MMP-9 (PDB 5CUH)(31) and gray for ADAM22 (PDB 3G5C).(32) MABS 1603”
BackgroundRios‐Doria, J., Sabol, D., Chesebrough, J. W., Stewart, D., XU, L. L., Tammali, R., Cheng, L., Du, Q., Schifferli, K. P., Rothstein, R., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1040 · Cited by 55
Camodeca, C., Nuti, E., Tepshi, L., Boero, S., Tuccinardi, T., Stura, E., Poggi, A., Zocchi, M., & Rossello, A. (2016) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2016.01.053 · Cited by 52
Stawikowska, R., Cudic, M., Giulianotti, M., Houghten, R. A., Fields, G. B., & Minond, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.462267 · Cited by 43 · cited 1×
“Based on studies involving short peptide-based substrates, the non-catalytic domains were shown not to directly interact with peptide substrates, but may regulate catalytic activity and affect substrate binding through steric hindrance.(13) Structural features of TACE ectodomain besides the conserved catalytic cleft m…”
BackgroundDasGupta, S., Murumkar, P. R., Giridhar, R., & Yadav, M. R. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.04.003 · Cited by 37 · cited 2×
“These inhibitors interact with the conserved catalytic cleft located on the surface of the ellipsoid-shaped M domain.(7,8,17,18) The catalytic cleft contains a catalytic zinc (Zn) ion at its center, coordinated by 4 highly conserved residues (H(405), E(406), H(409), H(415)) typical of a Zn-binding motif (HEXXHXXGXXHD…”
BackgroundMazzola, R., Zhu, Z., Sinning, L., McKittrick, B. A., Lavey, B. J., Spitler, J., Kozlowski, J. A., Neng-Yang, S., Zhou, G., Guo, Z., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.045 · Cited by 32
Kwok, H. F., Bøtkjær, K. A., Tape, C. J., Huang, Y., McCafferty, J., & Murphy, G. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu010 · Cited by 32 · cited 2×
“The binding mode of MEDI3622 also differs from previously reported anti-TACE inhibitory mAbs, D1(A12) and A9.”
MethodNovel methods and strategies in the discovery of TACE inhibitors
Murumkar, P. R., Giridhar, R., & Yadav, M. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.744745 · Cited by 31 · cited 1×
“Many small molecules antagonists against TACE have been reported.(6,7) They all bind the catalytic site of TACE, which is remarkably conserved across a disintegrin and metallopro-”
BackgroundBiaryl substituted hydantoin compounds as TACE inhibitors
Yu, W., Tong, L., Kim, S. H., Wong, M., Chen, L., Yang, D., Shankar, B. B., Lavey, B. J., Zhou, G., Kosinski, A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.134 · Cited by 28
Dai, C., Li, D., Popovici-Müller, J. V., Zhao, L., Girijavallabhan, V. M., Rosner, K. E., Lavey, B. J., Rizvi, R. K., Shankar, B. B., Wong, M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.002 · Cited by 27
Structure analysis reveals the flexibility of the ADAMTS‐5 active site
Shieh, H., Tomasselli, A. G., Mathis, K. J., Schnute, M. E., Woodard, S. S., Caspers, N. L., Williams, J. M., Kiefer, J. R., Munie, G. E., Wittwer, A. J., et al. (2011) · Protein Science · doi:10.1002/pro.606 · Cited by 22
Discovery of Selective Small Molecular TACE Inhibitors for the Treatment of Rheumatoid Arthritis
Li, N., Shi, Z. H., Tang, Y. P., Weili, Lian-Yin, & Duan, J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800672120 · Cited by 21 · cited 1×
“Such structural conservation of the catalytic active site has posed great challenges for the development specific TACE inhibitors.(12) In fact, early trials of TACE small molecule inhibitors have failed because of their off-target toxicities.”
Background
Cited by
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
“…studies employing ADAM17-neutralizing monoclonal antibodies that act via several modalities, including allosteric perturbation of the binding ability of its catalytic active site, or steric hindrance leading to competitive or noncompetitive inhibition of protein substrate binding 170,171 (Fig.”
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“MEDI3622 (anti-TACE antibody) showed promising preclinical activity in human colorectal adenocarcinoma progression [148, 149].”
BackgroundOvercoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177
“MEDI3622 is a human mAb of ADAM17 with high specificity and a potent inhibitory activity (163).”
BackgroundRecent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Moss, M. L., & Minond, D. (2017) · Mediators of Inflammation · doi:10.1155/2017/9673537 · Cited by 153
“Another ADAM17 inhibitory antibody (MEDI3622) was recently developed and studied in vitro, ex vivo, and in vivo [146, 147].”
BackgroundStrategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
Calligaris, M., Cuffaro, D., Bonelli, S., Spanò, D. P., Rossello, A., Nuti, E., & Scilabra, S. D. (2021) · Molecules · doi:10.3390/molecules26040944 · Cited by 130
“In addition, this cross-domain inhibitory antibody was proven to block tumor growth in vivo, when the human ovarian cancer cell line IGROV1-Luc was xenografted in Balb/c nude mice [213].”
Background
Metadata
- Authors
- Peng, L., Cook, K., Xu, L., Cheng, L., Damschroder, M., Gao, C., Wu, H., & Dall'Acqua, W. F.
- Corresponding author
- Peng, Li
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2016-09-09
- Volume
- 8
- Issue
- 8
- Pages
- 1598-1605
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC5098442
- OpenAlex
- W2518560246
- Cited by
- 30
- References
- 32
- Citations by year
- 2026: 2 · 2025: 6 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- mAbs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- ADAM17, transarterial chemoembolization, antibody specificity, M-domain, beta-hairpin loop, catalytic cleft, antibody-enzyme interaction, antibody design, structural modeling, molecular docking
- MeSH terms
- ADAM17 Protein, Antibodies, Monoclonal, Humans, Models, Molecular, Epitope Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.